Definition and Types of Disease Screening
Screening is the presumptive identification of unrecognised disease, pre-disease or risk factors in apparently healthy people using tests, examinations or procedures that can be applied rapidly. Screening separates people who are more likely to have the condition from those who are less likely; it does not by itself establish a final diagnosis.
Learning objectives
- Define screening and distinguish it from diagnosis, surveillance and case finding.
- Explain the purposes, benefits and limitations of screening.
- Describe mass, selective, multiphasic and opportunistic screening.
- State the criteria for a suitable disease, test and screening programme.
- Outline the screening pathway and ethical requirements.
Screening versus diagnostic testing
| Feature | Screening test | Diagnostic test |
|---|---|---|
| Population | Apparently healthy or asymptomatic people | People with symptoms, signs or a positive screening result |
| Purpose | Estimate probability and identify those needing further assessment | Confirm or exclude a specific diagnosis |
| Preferred qualities | Safe, simple, acceptable, affordable and usually sensitive | More specific and definitive; may be complex or invasive |
| Result | Screen-positive or screen-negative | Diagnosis confirmed, excluded or classified |
| Example | Blood-pressure measurement in asymptomatic adults | Repeated standard measurements and clinical evaluation for hypertension |
Purposes of screening
Early detection
Find disease during a latent or early stage when treatment may improve outcome.
Risk reduction
Identify risk factors such as raised blood pressure, obesity or dysglycaemia.
Protection of others
Detect transmissible conditions in defined circumstances and connect people to care.
Planning
Estimate service needs and guide prevention programmes, while recognising screening data are not complete surveillance data.
Types of screening
1. Mass or universal screening
A test is offered to a whole population group regardless of individual risk—for example, newborn screening or routine screening within a defined age group. It can achieve broad coverage but may require substantial resources and produce many false-positive results when disease prevalence is low.
2. Selective, targeted or high-risk screening
Screening is offered to people with a higher probability of disease because of age, family history, occupation, exposure, behaviour or another risk factor. It is more efficient than mass screening but can miss cases outside the selected group.
3. Multiphasic screening
Two or more screening tests are applied during the same encounter, such as measurement of blood pressure, body mass index, blood glucose and selected risk factors. It is convenient, but each test must still be evidence-based and linked to appropriate follow-up.
4. Opportunistic screening
Screening is offered when a person attends a health service for another reason—for example, checking blood pressure during an unrelated outpatient visit. It uses existing contact but may exclude people who rarely seek care.
5. Systematic or organised screening
An eligible population is identified, invited, screened, recalled and followed through a coordinated programme with quality assurance and evaluation. Organised programmes usually provide more equitable coverage than unplanned testing.
6. Sequential or two-stage screening
A simple sensitive test is applied first; those who test positive receive a more specific second test. This reduces unnecessary definitive investigations.
Criteria for a worthwhile screening programme
The condition
- It is an important health problem with a known burden.
- Its natural history is sufficiently understood.
- There is a detectable latent or early stage.
- Earlier treatment produces better outcomes than treatment after symptoms appear.
The test
- Valid, reliable, safe, acceptable and reasonably affordable.
- Suitable cut-off values and an agreed policy for borderline findings.
- Performance is appropriate for the target population.
The programme
- Facilities for confirmation, treatment and follow-up are available.
- Benefits outweigh physical, psychological, social and financial harms.
- Target population, interval and referral pathway are clearly defined.
- Quality assurance, informed choice, confidentiality and evaluation are built in.
The screening pathway
- Define the target population: use evidence-based eligibility criteria.
- Invite and educate: explain benefits, limitations and possible outcomes in understandable language.
- Obtain informed consent: participation should ordinarily be voluntary.
- Perform the test correctly: standardise equipment, technique and quality control.
- Communicate results: provide clear meaning and the next step.
- Confirm screen-positive results: use appropriate diagnostic assessment.
- Treat or manage: ensure timely linkage to effective services.
- Recall and follow up: track referrals, repeat tests and outcomes.
- Evaluate the programme: assess coverage, quality, harms, equity and health outcomes.
Possible outcomes of screening
| Outcome | Meaning | Implication |
|---|---|---|
| True positive | Test positive and disease present | Potential benefit from early diagnosis and care |
| False positive | Test positive but disease absent | Anxiety, cost and unnecessary investigations |
| True negative | Test negative and disease absent | Appropriate reassurance |
| False negative | Test negative but disease present | False reassurance and delayed diagnosis |
Benefits and potential harms
Potential benefits
- Reduced morbidity or mortality
- Less intensive treatment when disease is found early
- Opportunity for prevention and counselling
- More equitable access in organised programmes
Potential harms
- False-positive and false-negative results
- Overdiagnosis and overtreatment
- Procedure complications
- Anxiety, stigma and financial burden
- Inequity when follow-up care is unavailable
Important biases in screening
- Lead-time bias: survival appears longer simply because diagnosis was made earlier, even if death is not delayed.
- Length bias: screening preferentially detects slower-progressing disease with a longer detectable phase.
- Selection bias: people who participate may differ from those who do not.
- Overdiagnosis: detection of a condition that would never have caused symptoms or harm during the person's lifetime.
Worked example
A clinic offers blood-pressure measurement to all adults attending outpatient services. This is opportunistic screening. A raised single reading is not a final diagnosis: the patient needs correct repeat measurement, clinical assessment and follow-up. The programme should record coverage and ensure referral rather than merely counting tests.
Evaluating a screening programme
- Coverage: proportion of the eligible population screened.
- Uptake: proportion invited who attend.
- Positivity rate: proportion with a positive screening result.
- Referral completion: proportion of screen-positive people completing diagnostic assessment.
- Detection rate: confirmed cases found per number screened.
- Interval cases: cases diagnosed after a negative screen and before the next scheduled screen.
- Outcome and equity: effect on morbidity, mortality and gaps between population groups.
Exam-focused summary
- Screening identifies probability; diagnosis confirms disease.
- Mass screening covers a population; selective screening targets higher-risk groups.
- Multiphasic screening uses several tests; opportunistic screening occurs during another health encounter.
- A good programme requires a suitable condition, accurate acceptable test, effective early treatment and complete follow-up.
- Always consider false results, overdiagnosis, bias, consent, confidentiality and equity.
Review questions
- Define screening and differentiate it from diagnostic testing.
- Describe four types of screening and give an example of each.
- State the criteria for a suitable screening programme.
- Outline the screening pathway from invitation to evaluation.
- Explain lead-time bias, length bias and overdiagnosis.
References and further reading
- WHO: Screening programmes—guide to increase effectiveness.
- CDC: Screening resources.
- Clinical Medicine Year 2 curriculum.
Educational use only. Screening recommendations vary by age, risk and national guidance; follow current Uganda Ministry of Health and institutional protocols.
